Investor Presentaiton
Investor presentation
Full year 2018
Slide 32
Million
50
Region Europe at a glance
Diabetes trend in population
Population with diabetes
Diabetes market by value and
Novo Nordisk market share
Diabetes growth rate
NN Insulin MS
NN OAD MS
bDKK
80
Novo Nordisk reported sales
NN GLP-1 MS
Full year 2018
Sales
(mDKK)
Growth2
100%
Long-acting insulin³
4,282
10%
3%
Premix insulin4
1,701
(9%)
40
20.8%¹
80%
60
GLP-1
Fast-acting insulin5
4,558
5%
38
39
30
Human insulin
1,580
30
60%
(11%)
4.4%¹
40
Insulin
Total insulin
12,121
2%
20
40%
GLP-16
3,759
9%
20
10
N/A
0
0
2000
2017
2045
Nov
2013
10.4%¹
OAD
20%
Other diabetes care?
Diabetes care
579
(4%)
16,459
3%
Obesity (SaxendaⓇ)
207
104%
0%
Biopharm³
5,013
Nov
2018
Total
21,679
(2%)
3%
Europe Population 2018: ~0.6 billion people and diabetes prevalence
~8.8%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share comparison for Insulin as of Nov 2018:
Novo Nordisk 45%, Sanofi 35% and Eli Lilly 18%
Competitor value market share comparison for GLP-1 as of Nov 2018:
Novo Nordisk 55%, Eli Lilly 34% and AstraZeneca 10%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Nov, 2018 value figures
2 Percentage change in local currency from full year 2017 to full year
2018
3 Comprises Tresiba®, XultophyⓇ and Levemir®; 4 Comprises NovoMix®
and RyzodegⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ; 6 Comprises
VictozaⓇ and Ozempic®; 7 Comprises Novo NormⓇ and needles;
8Comprises primarily NovoSeven®, NovoEight®, NovoThirteen®, Refixia®,
Norditropin®, Vagifem® and ActivelleⓇView entire presentation